S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:COLL

Collegium Pharmaceutical - COLL Stock Forecast, Price & News

$23.99
-0.38 (-1.56%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$23.95
▼
$25.00
50-Day Range
$23.00
▼
$29.88
52-Week Range
$14.04
▼
$30.22
Volume
353,807 shs
Average Volume
344,971 shs
Market Capitalization
$817.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

Collegium Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
45.9% Upside
$35.00 Price Target
Short Interest
Bearish
17.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.78
Upright™ Environmental Score
News Sentiment
0.88mentions of Collegium Pharmaceutical in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.48 M Sold Last Quarter
Proj. Earnings Growth
22.45%
From $5.30 to $6.49 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

318th out of 996 stocks

Pharmaceutical Preparations Industry

145th out of 484 stocks

See Top Rated MarketRank™ Stocks Here

COLL stock logo

About Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Stock News Headlines

March 31, 2023 | markets.businessinsider.com
Cormedix (CRMD) Receives a Buy from Needham
March 26, 2023 | americanbankingnews.com
Collegium Pharmaceutical (NASDAQ:COLL) Share Price Passes Below 50 Day Moving Average of $26.62
April 2, 2023 | Vantage Point (Ad)
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
February 26, 2023 | finance.yahoo.com
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2022 Earnings Call Transcript
February 25, 2023 | seekingalpha.com
Collegium Pharmaceutical, Inc. 2022 Q4 - Results - Earnings Call Presentation
February 25, 2023 | seekingalpha.com
Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Call Transcript
February 24, 2023 | finance.yahoo.com
Q4 2022 Collegium Pharmaceutical Inc Earnings Call
February 23, 2023 | msn.com
Collegium Pharmaceutical Non-GAAP EPS of $1.09 misses by $0.17, revenue of $129.62M beats by $4.41M
April 2, 2023 | Vantage Point (Ad)
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
February 23, 2023 | msn.com
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates
February 22, 2023 | benzinga.com
Earnings Outlook For Collegium Pharmaceutical
February 22, 2023 | finance.yahoo.com
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
February 22, 2023 | finance.yahoo.com
Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
February 8, 2023 | msn.com
Collegium Pharmaceutical prices $210M senior notes
February 8, 2023 | finance.yahoo.com
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
February 7, 2023 | finanznachrichten.de
Collegium Pharmaceutical, Inc.: Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
February 6, 2023 | finance.yahoo.com
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
February 1, 2023 | nasdaq.com
Find 'Strong Buy' Stocks Near their Highs for February
January 29, 2023 | seekingalpha.com
Collegium Pharmaceutical: Low Multiples Justified, Growth To Come At A Cost
January 28, 2023 | finance.yahoo.com
Collegium Pharmaceutical's (NASDAQ:COLL) investors will be pleased with their decent 62% return over the last year
January 13, 2023 | marketwatch.com
Painful Diabetic Neuropathy Drug Market 2023 : Regional Scope, Growth Statistics, Demand and Regional Outlook 2029
January 11, 2023 | finance.yahoo.com
COLL vs. ZTS: Which Stock Is the Better Value Option?
January 4, 2023 | marketwatch.com
Collegium Pharmaceutical Shares Gain 11% on 2023 Guidance, Outlook
January 4, 2023 | msn.com
Collegium gains on 2023 financial guidance, $100M share buybacks
January 3, 2023 | marketwatch.com
Allergy Treatment Market 2023 : Trend Analysis, Competitive Outlook of Top Industry Players and Future Expansion by 2028
January 3, 2023 | benzinga.com
Mike Heffernan appointed Chairman of NMD Pharma's Board of Directors
December 22, 2022 | finance.yahoo.com
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
See More Headlines
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Company Calendar

Last Earnings
2/23/2023
Today
4/02/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COLL
CUSIP
N/A
CIK
1267565
Web
www.collegiumpharma.com
Phone
(781) 713-3699
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+45.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.74)
Trailing P/E Ratio
N/A
Forward P/E Ratio
4.53
P/E Growth
0.23
Net Income
$-25,000,000.00
Net Margins
-5.39%
Pretax Margin
-6.22%
Return on Equity
44.87%
Return on Assets
7.24%

Debt

Debt-to-Equity Ratio
2.76
Current Ratio
0.97
Quick Ratio
0.86

Sales & Book Value

Annual Sales
$463.93 million
Price / Sales
1.76
Cash Flow
$8.19 per share
Price / Cash Flow
2.93
Book Value
$5.80 per share
Price / Book
4.14

Miscellaneous

Outstanding Shares
34,070,000
Free Float
32,588,000
Market Cap
$817.34 million
Optionable
Optionable
Beta
0.81

Key Executives

  • Joseph J. CiaffoniJoseph J. Ciaffoni
    President, Chief Executive Officer & Director
  • Colleen TupperColleen Tupper
    Chief Financial Officer & Executive Vice President
  • Scott Sudduth
    Executive Vice President-Technical Operations
  • Thomas B. Smith
    Chief Medical Officer & Executive Vice President
  • Scott DreyerScott Dreyer
    Chief Commercial Officer & Executive VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













COLL Stock - Frequently Asked Questions

Should I buy or sell Collegium Pharmaceutical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COLL shares.
View COLL analyst ratings or view top-rated stocks.

What is Collegium Pharmaceutical's stock price forecast for 2023?

2 equities research analysts have issued 1 year price objectives for Collegium Pharmaceutical's shares. Their COLL share price forecasts range from $35.00 to $35.00. On average, they anticipate the company's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts price targets for COLL or view top-rated stocks among Wall Street analysts.

How have COLL shares performed in 2023?

Collegium Pharmaceutical's stock was trading at $23.20 on January 1st, 2023. Since then, COLL shares have increased by 3.4% and is now trading at $23.99.
View the best growth stocks for 2023 here.

When is Collegium Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our COLL earnings forecast.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its earnings results on Thursday, February, 23rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.10. The specialty pharmaceutical company earned $129.62 million during the quarter, compared to analyst estimates of $127.07 million. Collegium Pharmaceutical had a positive trailing twelve-month return on equity of 44.87% and a negative net margin of 5.39%.

What ETFs hold Collegium Pharmaceutical's stock?

ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include First Trust Dow Jones Select Microcap Index Fund (FDM), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO), iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $569.72 million.

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $23.99.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $817.34 million and generates $463.93 million in revenue each year. The specialty pharmaceutical company earns $-25,000,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

The company employs 152 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.

This page (NASDAQ:COLL) was last updated on 4/2/2023 by MarketBeat.com Staff